TRANSGENE
Research TRANSGENE (TNG.PA) on Bullrun: market cap EUR 194.78M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTNG.PA
- ExchangeXPAR
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 194.78M
- Financial periodFY2025
- RevenueEUR 490.00K
- Revenue growth59.6%
- Net income-EUR 37.52M
- Free cash flow-EUR 37.89M
Valuation Snapshot
latest market cap is EUR 194.78M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 490.00K | -EUR 37.52M | -EUR 37.89M | n/a | -0.26 | EUR 6.66M | EUR 0 | EUR 121.74M |
| FY2024 | EUR 307.00K | -EUR 33.97M | -EUR 26.62M | n/a | -0.29 | EUR 16.67M | EUR 17.00K | EUR 15.20M |
| FY2023 | EUR 1.45M | -EUR 22.33M | -EUR 37.42M | n/a | -0.22 | EUR 15.67M | EUR 1.26M | EUR 15.61M |
| FY2022 | EUR 3.47M | -EUR 32.80M | -EUR 21.84M | n/a | -0.33 | EUR 4.40M | EUR 2.45M | EUR 37.84M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-11 | EUR 194.78M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About TRANSGENE
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is TRANSGENE's market cap?
TRANSGENE's market capitalization is EUR 194.78M.
What does TRANSGENE do?
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors.